• No se han encontrado resultados

Mortalidad del paciente anciano con enfermedad cardiovascular en cuidados intensivos

N/A
N/A
Protected

Academic year: 2020

Share "Mortalidad del paciente anciano con enfermedad cardiovascular en cuidados intensivos"

Copied!
265
0
0

Texto completo

Loading

Figure

TABLA 2. ANTECEDENTES PERSONALES Y MORTALIDAD (EN UCI E INTRAHOSPITA- INTRAHOSPITA-LARIA)  Total  n= 202  Mortalidad UCI n= 202  p*  Mortalidad intrahospita-laria  n= 202  p*
TABLA 3.  TRATAMIENTO HABITUAL Y MORTALIDAD (EN UCI E INTRAHOSPITALA- INTRAHOSPITALA-RIA)  Total  n=  202 Mortalidad UCI n= 202 p* Mortalidad intrahospi-talaria n= 202 p*
TABLA 11. CARACTERÍSTICAS DEMOGRÁFICAS Y PSICOFUNCIONALES EN PACIENTES  CON  ANTECEDENTE  ENFERMEDAD  CARDIOVASCULAR  Y  MORTALIDAD  (EN  UCI  E  INTRAHOSPITAL)
TABLA 12. ANTECEDENTES PERSONALES EN PACIENTES CON ANTECEDENTE DE EN- EN-FERMEDAD CARDIOVASCULAR Y MORTALIDAD (EN UCI E INTRAHOSPITALARIA)
+7

Referencias

Documento similar

The main objective of this study was to determine whether the use of TXA in patients undergoing primary or revision TKR with a history of coronary artery disease increased

The incidence and prevalence of these diseases are increasingly globally, and although more research is needed to elucidate its role in pathologies such as atrial

Effects of resistance training on muscle strength, exercise capacity, and mobility in middle-aged and elderly patients with coronary artery disease: A meta-analysis.

INTRODUCTION The Association of Divorced Fathers (ADIF)and the Father-heart Association have formed a Hungarian Association Alliance, which has goals of

ilex leaf metabolome, the identification of novel metabolites with an emphasis on those with bioactivity previously reported, the characterization of tolerance to drought from

In support that this may be a cause for the insulin signalling defects, the replenishment of cholesterol to the hippocampus of old mice reduced PI3K/Akt activity, prevented

Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart

Evidence that non-lipid cardiovascular risk factors are associated with high prevalence of coronary artery disease in patients with heterozygous familial hypercholesterolemia